Navigation Links
Medivation Announces Participation in Upcoming Conferences
Date:8/28/2008

SAN FRANCISCO, Aug. 28 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences:

-- BioCentury's NewsMakers in the Biotech Industry on Thursday, September 4, at 9:00 a.m. Eastern Time at the Millennium Broadway Hotel & Conference Center

-- 2008 UBS Global Life Sciences Conference on Wednesday, September 24, at 4:30 p.m. Eastern Time at the Grand Hyatt New York

Dr. Hung will provide an overview of Medivation and its clinical development programs for Dimebon for Alzheimer's and Huntington's diseases and MDV3100 for prostate cancer.

A live audio webcast of each presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial. For more information, please visit us at http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
2. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
4. Medivation Announces Senior Management Promotions
5. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
6. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
7. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
8. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Jan. 20, 2017 Interpace Diagnostics Group, ... that provides clinically useful molecular diagnostic tests and ... into a securities purchase agreement with three  institutional ... of common stock in a registered direct offering.  ... agreed to sell to the same investors warrants ...
(Date:1/20/2017)... , January 20, 2017 Stock-Callers.com ... conditions have influenced the most recent performances of select ... (NASDAQ: RGLS ), Abeona Therapeutics Inc. (NASDAQ: ... TBPH ), and Sage Therapeutics Inc. (NASDAQ: ... by Grand View Research, global Biotech market size is expected to ...
(Date:1/19/2017)... Research Future has a half cooked research report on Global Liquid ... and expected to reach USD 450 Million by the end of ... ... assessed as a swiftly growing market and expected that the market ... There has been a tremendous growth in the prevalence of cancer ...
(Date:1/19/2017)... ... January 19, 2017 , ... November Research Group, ... biopharmaceutical and medical device manufacturers and regulators, is proud to announce the worldwide ... email client designed to provide product vigilance departments with the flexibility and ease ...
Breaking Biology Technology:
(Date:1/11/2017)... Intoxalock, a leading ignition interlock provider, has ... patent-pending calibration device. With this new technology, Intoxalock is ... data logs and process repairs at service center locations, ... drunk driving through the application of cutting-edge technologies is ... also for the customer who can get back on ...
(Date:1/6/2017)... Calif. , Jan. 6, 2017  Privately-held ... safety studies in healthy volunteers of a novel ... to treat acute pancreatitis. Acute ... typically a mild disorder, but can be very ... failure and sepsis, where extended hospital stays, time ...
(Date:1/6/2017)... Calif. , Jan. 5, 2017  Delta ID ... its iris scanning technology for automotive at CESĀ® 2017. ... GNTX ) to demonstrate the use of iris ... identify and authenticate the driver in a car, and ... during the driving experience. Delta ID and ...
Breaking Biology News(10 mins):